Unilife Corp was incorporated in Delaware on July 2, 2009 as a wholly owned subsidiary of UMSL. The Company is designer, manufacturer and supplier of injectable drug delivery systems that can enhance and differentiate the injectable drugs, biologics and vaccines, or collectively, injectable therapies, of pharmaceutical and biotechnology customers. Its products include pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems for the targeted delivery of injectable therapies. These products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Other products like reusable auto-injectors and certain systems for targeted drug delivery, are designed to either be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly by company to a health care provider or end user without having the device pre-filled by a pharmaceutical company. The Company's customers include Sanofi, MedImmune, AbbVie, Novartis and Hikma. The Company sells its products directly to pharmaceutical and biotechnology companies who incorporate them into the drug-device combination product that is supplied pre-filled and ready for administration by end-users such as health-care providers or patients. It competes with both public and private, which include Becton, Dickinson and Company, or BD, SCHOTT forma vitrum AG, Gerresheimer Bünde GmbH, West Pharmaceutical Services, Inc., Medtronic MiniMed, Inc., Insulet Corporation, and Ypsomed Group. As of July 2015, it had approximately 180 issued patents relating to its product platforms across more than 24 jurisdictions, including the U.S., the European Union, Australia, Japan, Israel, and China.